Reimagining Medicine
Company overview
Financial review
2023 priorities
Appendix
FINANCIAL PROFILE
Group Core Oplnc to grow mid single digit as sales growth and
SG&A savings partly offset by Gx erosion and Sandoz stand-up costs
2023 key drivers of core operating income (Group)
Vs. PY (cc) Illustrative
-
Impact of inflation expected to
continue in 2023
Gx erosion expected to increase due
to GilenyaⓇ US and LucentisⓇ EU
Stand-up investments to transition
Sandoz to a standalone company
+ In-market growth drivers to
continue growing strongly
+ Recent launches to further accelerate
+ China growth expected to accelerate
benefiting from return to normal in H2
+ Simplified organizational model to
deliver continued SG&A savings
+ Ongoing productivity programs.
-
-
44 Investor Relations | Q4 2022 Results
NOVARTIS | Reimagining MedicineView entire presentation